文献速递类风湿关节炎

早期类风湿关节炎:肠外与口服糖皮质激素对1年时停用激素及升级治疗的影响

Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year.
PubMed 文献 · Ann Rheum Dis · 2026-08-28

该研究基于加拿大早期关节炎队列2007至2023年2222例新诊断ERA患者,比较前3个月内不同糖皮质激素给药途径与12个月时持续使用GC或升级至先进治疗的风险。结果显示,与未用GC相比,口服GC持续使用OR为9.8,肠外GC为4.1;肠外GC患者12个月仍用GC的几率约为口服GC的一半,而升级治疗率组间相似。提示肠外GC可能有助于更早停用激素。

要点

  • 早期RA患者前3个月使用肠外GC者12个月持续用GC的几率约为口服GC的一半
  • 肠外GC与口服GC组12个月升级至先进治疗的比例相似
  • 与未用GC相比,口服和肠外GC持续使用OR分别为9.8和4.1

核心结论

  • 肠外GC患者12个月仍使用GC的几率约为口服GC患者的一半,升级治疗率组间相似,肠外GC可能促进更早停用激素。

研究设计与样本

  • 基于加拿大早期关节炎队列2007至2023年纳入的新诊断ERA成人(症状持续时间<1年)的观察性研究,排除基线前90天使用GC、3个月内已用先进治疗或随访<12个月者。
  • 共纳入2222例患者,中位(SD)年龄55(15)岁,病程5.5(3.0)个月,CDAI为26(14);按前3个月GC使用及途径分层,采用方差分析或Wilcoxon检验比较,并用调整多变量 logistic 回归计算OR。

主要发现

  • 前3个月内1661例(75%)未用GC,421例(19%)口服,121例(5%)肠外(关节内和/或肌内),19例(1%)口服联合肠外。
  • 12个月时,未用GC组先进治疗和GC使用分别为7%和8%;口服组为14%和47%;肠外组为14%和26%;联合组为16%和63%。
  • 与未用GC(OR=1.0)相比,1年时GC使用的OR为口服9.8、肠外4.1。

关键数值与推荐

  • 12个月时GC使用率:未用GC 8%,口服GC 47%,肠外GC 26%,口服联合肠外GC 63%。
  • 12个月时先进治疗使用率:未用GC 7%,口服GC 14%,肠外GC 14%,口服联合肠外GC 16%。
  • 1年时GC使用OR:口服GC 9.8,肠外GC 4.1,参照为未用GC(OR=1.0)。

临床怎么用

  • 在早期RA患者需短期GC桥接时,可考虑肠外给药以降低12个月持续使用激素的几率,但需结合患者具体情况个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to determine whether the route of glucocorticoid (GC) administration in patients with early rheumatoid arthritis (ERA) is associated with the odds of persistent GC use or escalation to advanced therapies at 12 months. METHODS: Adults with newly diagnosed ERA (symptoms duration <1 year) enrolled in the Canadian Early Arthritis Cohort between 2007 and 2023 were included. Those with GC use 90 days prior to baseline, on advanced therapy by 3 months, or with <12 months of follow-up were excluded. Patients were stratified by GC use and route in the first 3 months and compared using analysis of variance or Wilcoxon tests. Adjusted multivariable logistic regression was used to calculate the odds ratios (OR). RESULTS: Among 2222 patients, median (SD) age was 55 (15) years, disease duration 5.5 (3.0) months, and the Clinical Disease Activity Index was 26 (14). During the first 3 months, 1661 patients (75%) received no GC, 421 (19%) oral, 121 (5%) parenteral (intra-articular and/or intramuscular), and 19 (1%) both oral and parenteral. Advanced therapies and GC use, respectively, at 12 months were 7% and 8% (no GC); 14% and 47% (oral); 14% and 26% (parenteral); 16% and 63% (both). The OR for GC use at 1 year was 9.8 (oral) and 4.1 (parenteral), compared with no GC (1.0). CONCLUSIONS: Patients receiving parenteral GC were half as likely to remain on GC at 12 months compared with those on oral GC. Rates of advanced therapy use were similar between groups. Parenteral GC administration may facilitate earlier discontinuation of steroids.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fernández-Codina A, Bartlett SJ, Thorne C, et al. Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year. Ann Rheum Dis. 2026. PMID: 42665531. doi:10.1016/j.ard.2026.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。